369 related articles for article (PubMed ID: 35241844)
1. Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial.
Chu L; Vrbicky K; Montefiori D; Huang W; Nestorova B; Chang Y; Carfi A; Edwards DK; Oestreicher J; Legault H; Dutko FJ; Girard B; Pajon R; Miller JM; Das R; Leav B; McPhee R
Nat Med; 2022 May; 28(5):1042-1049. PubMed ID: 35241844
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C; Lazarus R; Dellago H; Maurer G; Weisova P; Corbic-Ramljak I; Dubischar K; Lilja A; Eder-Lingelbach S; Hochreiter R; Jaramillo JC; Junker H; Krammer M; Pusic P; Querton B; Larcher-Senn J; Hoffmann M; Pöhlmann S; Finn A;
J Infect; 2023 Sep; 87(3):242-254. PubMed ID: 37406777
[TBL] [Abstract][Full Text] [Related]
3. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
[TBL] [Abstract][Full Text] [Related]
4. Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
Dixit A; Bennett R; Ali K; Griffin C; Clifford RA; Turner M; Poston R; Hautzinger K; Yeakey A; Girard B; Zhou W; Deng W; Zhou H; Schnyder Ghamloush S; Kuter BJ; Slobod K; Miller JM; Priddy F; Das R;
Lancet Infect Dis; 2024 Jul; 24(7):687-697. PubMed ID: 38518789
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of COReNAPCIN, a SARS-CoV-2 mRNA vaccine, as a fourth heterologous booster in healthy Iranian adults: A double-blind, randomized, placebo-controlled, phase 1 clinical trial with a six-month follow-up.
Salehi M; Alavi Darazam I; Nematollahi A; Alimohammadi M; Pouya S; Alimohammadi R; Khajavirad N; Porgoo M; Sedghi M; Mahdi Sepahi M; Azimi M; Hosseini H; Mahmoud Hashemi S; Dehghanizadeh S; Khoddami V
Int Immunopharmacol; 2024 Jun; 134():112192. PubMed ID: 38761778
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.
Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI
Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141
[TBL] [Abstract][Full Text] [Related]
7. Safety and Immunogenicity of a 100 μg mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2).
Chalkias S; Schwartz H; Nestorova B; Feng J; Chang Y; Zhou H; Dutko FJ; Edwards DK; Montefiori D; Pajon R; Leav B; Miller JM; Das R
medRxiv; 2022 Mar; ():. PubMed ID: 35291289
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and safety of a single booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Primary analysis report of a phase 3 open-label trial.
Kuriyama K; Murakami K; Masuda T; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2023 Jun; 41(25):3763-3771. PubMed ID: 37198021
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of a second heterologous booster dose of NVX-CoV2373 (TAK-019) in healthy Japanese adults who had previously received a primary series of COVID-19 mRNA vaccine: Interim analysis report of a phase 3 open-label trial.
Kuriyama K; Murakami K; Sugiura K; Sakui S; Schuring RP; Mori M
Vaccine; 2024 Jan; 42(3):662-670. PubMed ID: 38129286
[TBL] [Abstract][Full Text] [Related]
10. Three-month antibody persistence of a bivalent Omicron-containing booster vaccine against COVID-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Ying Chang ; Sutherland A; Montefiori DC; Girard B; Edwards DK; Jing Feng ; Zhou H; Baden LR; Miller JM; Das R
Nat Commun; 2023 Aug; 14(1):5125. PubMed ID: 37612300
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of SARS-CoV-2 variant mRNA vaccine boosters in healthy adults: an interim analysis.
Choi A; Koch M; Wu K; Chu L; Ma L; Hill A; Nunna N; Huang W; Oestreicher J; Colpitts T; Bennett H; Legault H; Paila Y; Nestorova B; Ding B; Montefiori D; Pajon R; Miller JM; Leav B; Carfi A; McPhee R; Edwards DK
Nat Med; 2021 Nov; 27(11):2025-2031. PubMed ID: 34526698
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity and safety of single booster dose of KD-414 inactivated COVID-19 vaccine in adults: An open-label, single-center, non-randomized, controlled study in Japan.
Terada-Hirashima J; Takamatsu Y; Shimizu Y; Uemura Y; Takeuchi JS; Tomita N; Matsuda K; Maeda K; Yamamoto S; Fukunaga A; Ohmagari N; Mikami A; Sonoda K; Ujiie M; Mitsuya H; Sugiura W
Hum Vaccin Immunother; 2023 Dec; 19(1):2193074. PubMed ID: 37052247
[TBL] [Abstract][Full Text] [Related]
13. A Bivalent Omicron-Containing Booster Vaccine against Covid-19.
Chalkias S; Harper C; Vrbicky K; Walsh SR; Essink B; Brosz A; McGhee N; Tomassini JE; Chen X; Chang Y; Sutherland A; Montefiori DC; Girard B; Edwards DK; Feng J; Zhou H; Baden LR; Miller JM; Das R
N Engl J Med; 2022 Oct; 387(14):1279-1291. PubMed ID: 36112399
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of a bivalent SARS-CoV-2 protein booster vaccine, SCTV01C, in adults previously vaccinated with mRNA vaccine: a randomized, double-blind, placebo-controlled phase 1/2 clinical trial.
Hannawi S; Saifeldin L; Abuquta A; Alamadi A; Mahmoud SA; Hassan A; Liu D; Yan L; Xie L
EBioMedicine; 2023 Jan; 87():104386. PubMed ID: 36470077
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
[TBL] [Abstract][Full Text] [Related]
16. Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose.
Roozen GVT; Prins MLM; Prins C; Janse JJ; de Gruyter HLM; Pothast CR; Huisman W; Koopman JPR; Lamers OAC; Kuijer M; Myeni SK; van Binnendijk RS; Hartog GD; Heemskerk MHM; Jochems SP; Feltkamp MCW; Kikkert M; Rosendaal FR; Roestenberg M; Visser LG; Roukens AHE
Clin Microbiol Infect; 2024 Jul; 30(7):930-936. PubMed ID: 38552793
[TBL] [Abstract][Full Text] [Related]
17. A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults.
Kulkarni PS; Gunale B; Kohli S; Lalwani S; Tripathy S; Kar S; Raut S; Kulkarni P; Apte A; Bavdekar A; Bhalla HL; Plested JS; Cloney-Clark S; Zhu M; Kalkeri R; Pryor M; Hamilton S; Thakar M; Sannidhi RS; Baranwal P; Bhamare C; Dharmadhikari A; Gupta M; Poonawalla CS; Shaligram U; Kapse D;
Sci Rep; 2023 Oct; 13(1):16579. PubMed ID: 37789040
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of primary vaccination with a SARS-CoV-2 mRNA vaccine (SYS6006) in Chinese participants aged 18 years or more: Two randomized, observer-blinded, placebo-controlled and dose-escalation phase 1 clinical trials.
Chen GL; Qiu YZ; Wu KQ; Wu Y; Wang YH; Zou YY; Peng CG; Zhao J; Su C; Ma JH; Ni SN; Wang X; Jin TH; Jiang Q; Guo T; Xu Y; Huang CC; Zhang Q; Liu KL; Ji L; Yang HY; Li CL; Su YW; Lu X; Li LJ
Hum Vaccin Immunother; 2023 Dec; 19(3):2285089. PubMed ID: 38111106
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373.
Alves K; Plested JS; Galbiati S; Chau G; Cloney-Clark S; Zhu M; Kalkeri R; Patel N; Smith K; Marcheschi A; Pfeiffer S; McFall H; Smith G; Glenn GM; Dubovsky F; Mallory RM;
Vaccine; 2023 Jun; 41(29):4280-4286. PubMed ID: 37271706
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a SARS-CoV-2 mRNA vaccine (SYS6006) in healthy Chinese participants: A randomized, observer-blinded, placebo-controlled phase 2 clinical trial.
Jin F; Qiu Y; Wu Z; Wang YH; Cai C; Fu L; Jiao W; Wang H; Gao M; Su C; Ma JH; Xu Y; Huang CC; Zhang Q; Ni S; Zhao M; Guo L; Ji L; Yang H; Zhao Y; Li C; Lu X; Su YW; Li Q
Vaccine; 2024 Mar; 42(7):1561-1570. PubMed ID: 38365485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
